IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No.:	**09/911,692**	Group Art Unit:	1644
Confirmation No.:	8484	Examiner:	R. Schwadron
Filed:	25 July 2001		
Applicant:	Darrell R. ANDERSON et al.		
For:	Expression and Use of Anti-CD20 Antibodies		

Mail Stop **Amendment**
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In compliance with the requirements and provisions of 37 C.F.R. §§ 1.56, 1.97, and 1.98, applicant cites the documents listed on the Form PTO-1449 that accompanies this paper. Copies of the cited documents, except for U.S. patent documents, are also provided. Applicant does not represent that a search has been conducted or that the cited documents are prior art against the claims in this application.

This disclosure statement is filed after a first action on the merits under the provisions of 37 C.F.R. § 1.97(c)(2). Applicant requests that the Director charge the IDS fee (§ 1.17(p)) of **$180,** as well as any additional fee required to support consideration of this statement, to our **Deposit Account No. 18-1260.**

Applicant requests that the examiner indicate consideration of the cited references.

Respectfully submitted,

/David L. Fitzgerald/

David L. Fitzgerald, Reg. No. 47,347
Attorney for Biogen Idec Inc.

SIDLEY AUSTIN LLP
1501 K Street, N.W.
Washington, DC 20005

tel. (202) 736-8818
fax (202) 736-8711

INFORMATION DISCLOSURE STATEMENT	Docket No. 27693-01009	**Serial No:** **09/ 911,692**
	Inventor(s): D.R. ANDERSON *et al.*	Examiner: R. Schwadron
	Filed: 25 July 2001	Art Unit: 1644

U.S. PATENT DOCUMENTS

INITIAL	INDEX	DOCUMENT	DATE	NAME	CLASS	SUB.	FILING DATE
	D1	4,831,175	16 May 1989	Gansow			
	D2	5,099,069	24 Mar 1992	Gansow			
	D3	5,124,471	23 Jun 1992	Gansow			
	D4	5,246,692	21 Sep 1993	Gansow			
	D5	5,286,850	15 Feb 1994	Gansow			
	D6	5,460,785	24 Oct 1995	Rhodes			
	D7	2003/ 0095963 A1	22 May 2003	Anderson			
	D8	2004/ 0167319 A1	26 Aug 2004	Teeling			

FOREIGN PATENT DOCUMENTS

INITIAL	INDEX	DOCUMENT	DATE	COUNTRY	CLASS	SUB.	TRANSLATION	
	D9	0 669 836 B1	7 Mar 1996	EP				
	D10	0 752 248 A1	8 Jan 1997	EP				
	D11	87/ 02671 A1	7 May 1987	WO				
	D12	89/ 00999 A1	9 Feb 1989	WO				
	D13	93/ 02108 A1	4 Feb 1993	WO				
	D14	00/ 27428 A1	18 May 2000	WO				
	D15	00/ 27433 A1	18 May 2000	WO				
	D16	01/ 10460 A1	15 Feb 2001	WO				

EXAMINER	**DATE CONSIDERED**

Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE STATEMENT	Docket No. 27693-01009	**Serial No:** **09/ 911,692**
	Inventor(s): D.R. ANDERSON *et al.*	Examiner: R. Schwadron
	Filed: 25 July 2001	Art Unit: 1644

OTHER DOCUMENTS

INITIAL	INDEX	CITATION
	D17	Anderson D.R. et al. *Biochem. Soc. Trans.* 25(2): 705-08, 1997. Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma.
	D18	Armitage J.O. et al. *J. Clin. Oncol.* 16(8): 2780-95, 1998. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project.
	D19	Berinstein N.L. et al. *Ann. Oncol.* 9: 995-1001, 1998. Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma.
	D20	Beychok S. (in) *Cells of Immunoglobulin Synthesis*, B. Pernis et al., eds. New York: Academic Press, 1979, 69-88. Comparative aspects of *in vitro* and cellular assembly of immunoglobulins.
	D21	Buchsbaum D.J. et al. *Cancer Res.* 52: 637-642, 1992. Improved delivery of radiolabeled anti-B1 monoclonal antibody to Raji lymphoma xenografts by predosing with unlabeled anti-B1 monoclonal antibody.
	D22	Carrasquillo J.A. et al. *J. Nucl. Med.* 26: 67, abst. no. 276, 1985. Improved imaging of metastatic melanoma with high dose 9.2.27 In-111 monoclonal antibody.
	D23	Chinn P.C. et al. *Int. J. Oncol.* 15(5): 1017-25, Nov. 1999. Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma.
	D24	Chinn P.C. et al. *Proc. Ann. Mtg. Am Assn. Cancer Res.* 40: 574, abst. no. 3786, 1999. A ^{90}Y-labeled anti-CD20 monoclonal antibody conjugated to MX-DTPA, a high-affinity chelator for yttrium.
	D25	Cogliatti S.B. et al. *Sw. Med. Weekly* 192: 607-17, 2002. Who is *WHO* and what was *REAL*?
	D26	Davis T.A. et al. *Clin. Cancer Res.* 5(3): 611-15, 1999. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression.
	D27	Davis T.A. et al. *Proc. Ann. Mtg. Amer. Assn. Cancer Res.* 39: 435, abst. no. 2964, 1998. Therapy of B cell lymphoma with anti-CD20 can result in relapse with loss of CD20 expression.
	D28	Dillman R.O. *J. Clin. Oncol.* 12(7): 1497-1515, 1994. Antibodies as cytotoxic therapy.

EXAMINER	**DATE CONSIDERED**

Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE STATEMENT	Docket No. 27693-01009	**Serial No:** **09/ 911,692**
	Inventor(s): D.R. ANDERSON *et al.*	Examiner: R. Schwadron
	Filed: 25 July 2001	Art Unit: 1644

INITIAL	INDEX	CITATION
	D29	Grillo-López A.J. IBC Int'l. Conference on Antibody Engineering, La Jolla, December 1994. IDEC-C2B8 chimeric antibody and IDEC-Y2B8 radiolabeled antibody phase I and II studies in patients with non-Hodgkin's lymphoma (abstract of presentation).
	D30	Grillo-López A.J. et al. *Ann. Oncol.* 7(3 Suppl.): 57, abst. no. 195, 1996. Treatment (rx) of relapsed non-Hodgkin's lymphoma (NHL) using the 90-yttrium (90-Y) labeled anti-CD20 monoclonal antibody (MAB) IDEC-Y2B8: a phase I clinical trial (PI CT).
	D31	Grillo-López A.J. et al. *Antibody Immunoconj. Radiopharm.* 8: 60, abst. no. 10, 1995. Treatment options for patients with relapsed low-grade or follicular lymphoma: the role of IDEC-C2B8.
	D32	Grillo-López A.J. et al. *Blood* (86(10 Suppl. 1): 55a, abst. no. 207, 1995. Phase I study of IDEC-Y2B8: 90-yttrium labeled anti-CD20 monoclonal antibody therapy of relapsed non-Hodgkin's lymphoma.
	D33	Grillo-López A.J. et al. *Br. J. Haematol.* 93(Suppl. 2): 283, abst. no. 1072, 1996. IDEC-C2B8 chimeric anti-CD20 antibody (MAB): safety and clinical activity in the treatment of patients (PTS) with relapsed low-grade or follicular (IWF:A-D) non-Hodgkin's lymphoma (NHL).
	D34	Horning S.J. et al. *Blood* 100(11 part 1): 357a, abst. no. 1385, 2002. Rituximab treatment failures: tositumomab and Iodine I 131 tositumomab (Bexxar®) can produce meaningful durable responses.
	D35	IDEC Pharmaceuticals Corp. and Genentech, Inc., Product insert for RITUXAN® approved by U.S. Food and Drug Administration on 26 November 1997.
	D36	Janakirman N. et al. *Blood* 92(10 Suppl. 1): 337a, abst. no. 1384, Nov. 1998. Rituximab: correlation between effector cells and clinical activity in NHL.
	D37	Kinoshita T. et al. *J. Clin. Oncol.* 16(12): 3916, Dec. 1998. CD20-negative relapse in B-cell lymphoma after treatment with Rituximab.
	D38	Maloney D.C. et al. *Blood* 90(6): 2188-2195, 1997. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma.
	D39	Maloney D.G. et al. *Blood* 88(10: Suppl. 1): 637a, abst. no. 2635, 1996. The anti-tumor effect of monoclonal anti-CD20 antibody (mAb) therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma (NHL) cell lines.

EXAMINER	**DATE CONSIDERED**

Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE STATEMENT	Docket No. 27693-01009	**Serial No:** **09/ 911,692**
	Inventor(s): D.R. ANDERSON *et al.*	Examiner: R. Schwadron
	Filed: 25 July 2001	Art Unit: 1644

INITIAL	INDEX	CITATION
	D40	Maloney D.G. et al. *J. Clin. Oncol.* 15(10): 3266-3274, Oct. 1997. IDEC-C2B8: results of a phase 1 multiple-dose trial in patients with relapsed non-Hodgkin's Lymphoma.
	D41	Maloney D.M. et al. *Blood* 84(8): 2457-66, 1994. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma.
	D42	McLaughlin P. et al. *Blood* 92(10 Suppl. 1): 414a-415a, abst. no. 1712, Nov. 1998. Efficacy controls and long-term follow-up for relapsed or refractory, low-grade or follicular (R-LG/F) NHL.
	D43	McLaughlin P. et al. *J. Clin. Oncol.* 16(8): 2825-2833, Aug. 1998. Rituximab chimeric-anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.
	D44	McLaughlin P. et al. *Oncology* 12(12): 1763-81, 1998. Clinical status and optimal use of rituximab for B-cell lymphomas.
	D45	Non-Hodgkin's Lymphoma Pathologic Classification Project. *Cancer* 49(10): 2112-35, 1982. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas.
	D46	Pietersz G.A. et al. *Immunol. Cell. Biol.* 65(2): 111-25, 1987. The use of monoclonal antibody conjugates for the diagnosis and treatment of cancer.
	D47	Piro L.D. et al. *Ann. Oncol.* 10: 655-61, 1999. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma.
	D48	Press O.W. *Cancer J. Sci. Amer.* 4(Suppl 2): S19-S26, Jul. 1998. Prospects for the management of non-Hodgkin's lymphomas with monoclonal antibodies and immunoconjugates.
	D49	Teeling J.L. et al. *Blood* 104:1793-1800, 2004. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas.
	D50	Teeling J.L. et al. *J. Immunol.* 277: 362-71, 2006. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20.
	D51	White C.A. et al. *Ann. Oncol.* 10(3 Suppl): 64, abst. no. 215, 1999. Radioimmunotherapy of relapsed or refractory non-Hodgkin's lymphoma (NHL): IDEC-Y2B8 phase I/II ^{90}yttrium trial.
	D52	White C.A. et al. *Ann. Rev. Med.* 52: 125-45, 2001. Antibody-targeted immunotherapy for treatment of malignancy.
	D53	White C.A. et al. *Blood* 87(9): 3640-49, 1996. Radioimmunotherapy of relapsed B-cell lymphoma with Yttrium 90 anti-idiotype monoclonal antibodies.

EXAMINER	**DATE CONSIDERED**

Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE STATEMENT	Docket No. 27693-01009	**Serial No:** **09/ 911,692**
	Inventor(s): D.R. ANDERSON *et al.*	Examiner: R. Schwadron
	Filed: 25 July 2001	Art Unit: 1644

INITIAL	INDEX	CITATION
	D54	White C.A. et al. *Eur. J. Cancer* 35: S57, abst. no. 107, 1999. Zevalin™ radioimmunotherapy of relapsed or refractory non-Hodgkin's lymphoma.
	D55	Witzig T. et al. *Blood* 90(10 Suppl. 1): 586a, abst. no. 2606, 1997. IDEC-Y2B8 ^{90}yttrium anti-CD20 radioimmunotherapy of relapsed non-Hodgkin's lymphoma (NHL): interim results of a phase I/II trial.
	D56	Witzig T.E. et al. *J. Clin. Oncol.* 17(12): 3793-3803, 1999. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma.
	D57	Witzig T.E. et al. *J. Clin. Oncol.* 20: 2453-63, 2002. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
	D58	Witzig T.E. et al. *Blood* 94(10 Suppl. 1): 631a, abst. no. 2805, 1999. Prospective randomized controlled study of ZEVALIN™ (IDEC-Y2B8) radioimmunotherapy compared to rituximab immunotherapy for B-cell NHL: report of interim results.

EXAMINER	**DATE CONSIDERED**

Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.